文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病

随机临床试验:按需沃诺拉赞对比安慰剂治疗非糜烂性反流病的疗效与安全性

Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-09-26

本研究为随机临床试验,纳入非糜烂性反流病(NERD)患者,先经4周沃诺拉赞20 mg每日一次导入期,再将无烧心且依从性达标者按1:1:1:1随机分为沃诺拉赞10、20、40 mg按需治疗组或安慰剂组,疗程6周。主要终点为按需给药后3小时内烧心发作完全缓解并持续24小时的比例,各沃诺拉赞组均显著高于安慰剂组,未报告严重治疗中出现的不良事件。

要点

  • 按需沃诺拉赞10、20、40 mg组烧心发作完全持续缓解率分别为56.0%、60.6%、70.0%,均显著高于安慰剂组的27.3%(p<0.0001)。
  • 给药后1小时,沃诺拉赞组达到完全缓解的烧心发作数显著多于安慰剂组。
  • 未报告严重治疗中出现的不良事件,按需沃诺拉赞可能成为NERD持续性抑酸治疗的潜在替代方案。

核心结论

  • 按需沃诺拉赞可能成为NERD患者发作性烧心缓解中持续性每日抑酸治疗的潜在替代方案。

研究设计与样本

  • 随机临床试验,NERD定义为烧心≥6个月且连续≥4/7天伴内镜检查正常,导入期每日一次沃诺拉赞20 mg共4周。
  • 导入期后无烧心持续7天且研究药物与日记依从性≥80%的患者按1:1:1:1随机接受沃诺拉赞10、20、40 mg或安慰剂按需治疗6周。
  • 导入期458例患者,进入按需治疗期207例。

主要发现

  • 沃诺拉赞10 mg组56.0%(201/359)的可评估烧心发作达到完全且持续缓解,20 mg组60.6%(198/327),40 mg组70.0%(226/323),安慰剂组27.3%(101/370),各沃诺拉赞组对比安慰剂p<0.0001。
  • 给药后1小时,沃诺拉赞组达到完全缓解的烧心发作数显著多于安慰剂组。
  • 未报告严重治疗中出现的不良事件。

关键数值与推荐

  • 主要终点为按需给药后3小时内烧心发作完全缓解并持续24小时的比例。
  • 沃诺拉赞10 mg组56.0%(201/359)对比安慰剂组27.3%(101/370),p<0.0001。
  • 沃诺拉赞20 mg组60.6%(198/327)对比安慰剂组27.3%(101/370),p<0.0001。
  • 沃诺拉赞40 mg组70.0%(226/323)对比安慰剂组27.3%(101/370),p<0.0001。

临床怎么用

  • 原文结论认为按需沃诺拉赞可能成为NERD患者发作性烧心缓解中持续性每日抑酸治疗的潜在替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-erosive reflux disease (NERD) symptoms are often episodic, making on-demand treatment an attractive treatment approach. AIMS: We compared the efficacy and safety of on-demand vonoprazan versus placebo in patients with NERD. METHODS: Patients with NERD, defined as heartburn for ≥6 months and for ≥4/7 consecutive days with normal endoscopy, received once-daily vonoprazan 20 mg during a 4-week run-in period. Patients without heartburn during the last 7 days and with ≥80% study drug and diary compliance were randomised 1:1:1:1 to vonoprazan 10, 20, 40 mg or placebo on-demand for 6 weeks. The primary endpoint was the percentage of evaluable heartburn episodes completely relieved within 3 h of on-demand dosing and sustained for 24 h. RESULTS: Of 458 patients in the run-in period, 207 entered the on-demand period. In the vonoprazan 10 mg group, 56.0% (201/359) of evaluable heartburn episodes met the criteria for complete and sustained relief; 60.6% (198/327) in the 20 mg group; and 70.0% (226/323) in the 40 mg group, compared with 27.3% (101/370) in the placebo group (p < 0.0001 versus placebo for each vonoprazan group). By 1 h post-dose, vonoprazan was associated with complete relief of significantly more heartburn episodes compared with placebo. No serious treatment-emergent adverse events were reported. CONCLUSION: On-demand vonoprazan may be a potential alternative to continued daily acid suppression therapy for the relief of episodic heartburn in patients with NERD. CLINICALTRIALS: gov: NCT04799158.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fass R, Vaezi M, Sharma P, et al. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Aliment Pharmacol Ther. 2023. PMID: 37750406. doi:10.1111/apt.17728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。